|
|
|
|
|
|
|
|
|
|
OXiGENE confirms tolerability in second toxicity analysis of ovarian cancer drug trial - Pharmaceutical Business Review
"As part of the analysis, performed at more than 80 US locations, patients were given the combination of ZYBRESTAT (fosbretabulin tromethamine or CA4P) and Avastin (bevacizumab) and evaluated the toxicity.
Patients are randomized with bevacizumab 15 mg/kg IV in one arm and bevacizumab plus fosbretabulin tromethamine 60 mg/m2 IV in the other arm on the first day as part of the therapy and every three weeks.....
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.